Innovation Pharmaceuticals Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Innovation Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company primarily engaged in the development of innovative therapies targeting infectious diseases and other unmet medical needs. Its core product is Brilacidin, a first-in-class immunomodulatory drug candidate with broad-spectrum antimicrobial and anti-inflammatory properties. The company is advancing Brilacidin for multiple therapeutic applications, including oral mucositis—a severe side effect of chemoradiation therapy—and other infectious disease indications. Additionally, Innovation Pharmaceuticals is developing BeaMed, a novel image-guided surgical laser platform aimed at treating cancer and epilepsy. The company focuses on delivering cutting-edge medical therapies by leveraging immune system modulation and antimicrobial technologies. Innovation Pharmaceuticals is headquartered in the United States and has a development pipeline leveraging pre-clinical and clinical trial results from over 500 patients treated with Brilacidin. The drug candidate has obtained FDA Fast Track designation due to its potential to address significant unmet medical needs. Recent major developments include ongoing clinical trials for oral mucositis with top-line data expected by the fourth quarter of 2025. The company is also actively engaged in research collaborations with government agencies and academic institutions to explore additional antiviral applications of Brilacidin, including non-SARS-CoV-2 endemic viral diseases. Furthermore, Innovation Pharmaceuticals reports strategic progress in its BeaMed Technologies segment, with breakthroughs in fiber optic probe development to enhance its StingRay Laser system for broader therapeutic use. Founded in 2005 and headquartered in New Haven, Connecticut, Innovation Pharmaceuticals conducts operations primarily in the U.S. Its target markets span multiple segments within infectious diseases, oncology, and neurology, focusing on patient populations facing limited effective treatment options. The company’s product development strategy emphasizes clinical stage advancement of its lead candidates while securing designations and partnerships that facilitate regulatory progression and commercialization readiness. Innovation Pharmaceuticals is publicly traded under the ticker IPIX and continues to expand its pipeline through both internal development and external collaborations. The company regularly updates investors with trial progress and regulatory milestones, positioning itself as a growing biopharma entity dedicated to next-generation therapeutic solutions for difficult-to-treat conditions. Recent operational updates highlight a clinical milestone on schedule for a 510(k) FDA submission for the BeaMed system in mid-2024 and ongoing enrollment completions in oral mucositis trials, underpinning its forward momentum in both drug and medical device domains. These advances illustrate the company’s dual focus on pharmaceutical drug development and innovative medical technology platforms.
AdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, Massachusetts
INVNT™ Announced as Sponsor and Co-Producer of Discovery Stage at SXSW Sydney® 2024
Innovation Pharmaceuticals Announces New Milestone at BeaMed; On Track to File 510(k) Submission to FDA in Q2 2024
Innovation Pharma Announces New Brilacidin Antiviral Research on Non-SARS-CoV-2 Endemic Viral Diseases to be Presented at the 2021 Military Health System Research Symposium
Patient Enrollment Reaches 90 Percent in Innovation Pharmaceuticals Phase 2 Clinical Trial of Brilacidin for COVID-19
Innovation Pharma Surpasses 50 Percent Enrollment in Phase 2 Clinical Trial of Brilacidin for COVID-19
Innovation Pharma's Broad Spectrum Antiviral Drug Candidate Brilacidin Highlighted in Biodefense and Infectious Diseases COVID-19 Presentation
Innovation Pharma Announces Brilacidin Abstract Accepted for Oral Presentation at the American Society for Virology's Annual Meeting
Innovation Pharma Completes Interim Safety Data Review—DMC Approves Increased Dosing Frequency in Phase 2 Clinical Trial of Brilacidin in Hospitalized COVID-19 Patients
Innovation Pharma's COVID-19 Drug Candidate Brilacidin Ranked in Top Three Percent of Compounds Predicted to Be Most Effective Against SARS-CoV-2
Recruitment and Enrollment Underway at Eight Sites for Innovation Pharma's Phase 2 Clinical Trial of Brilacidin for COVID-19
Innovation Pharmaceuticals' Phase 2 Clinical Trial of Brilacidin for Treating COVID-19 Scheduled to Begin Next Week
Innovation Pharmaceuticals' Brilacidin for the Treatment of COVID-19 Receives FDA Fast Track Designation